MicroventionTerumo

News & Press

Apr 11, 2023

Costa Rica's President Rodrigo Chaves Robles Recognizes MicroVention's Achievements with its Door To The Future Program and Signs National Employment Program Decree at MicroVention

Aliso Viejo, California andAlajuela, Costa Rica, April 11, 2023 – MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today hosted the Republic of Costa Rica’s President Rodrigo Chaves Robles and other government officials and dignitaries at its Costa Rica facility in Alajuela.

Ordering Information

Apr 11, 2023

Costa Rica's President Rodrigo Chaves Robles Recognizes MicroVention's Achievements with its Door To The Future Program and Signs National Employment Program Decree at MicroVention

Aliso Viejo, California andAlajuela, Costa Rica, April 11, 2023 – MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today hosted the Republic of Costa Rica’s President Rodrigo Chaves Robles and other government officials and dignitaries at its Costa Rica facility in Alajuela.

Sep 29, 2022

MicroVention Celebrates 25 Years in Neuroendovascular Technologies that Improve Patient Lives

MicroVention, Inc., a global neurovascular company and a wholly owned subsidiary of Terumo Corporation, celebrates its 25-year anniversary on September 29, 2022. Founded in 1997 by a handful of Associates in Southern California, MicroVention is now a worldwide community with over 3,000 Associates and distributors worldwide, with offices across the United States, Europe, Asia, and Costa Rica.

Aug 22, 2022

MicroVention Earns 2022 Great Place to Work Certification™

The prestigious award is based entirely on what current employees say about their experience working at MicroVention. This year, 80% of employees said it’s a great place to work – 21 points higher than the average U.S. company.

Apr 20, 2022

MicroVention Announces First Patient Enrolled in the STRAIT Study with the New BOBBY™ Balloon Guide Catheter

MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced the successful completion of its first enrollment in a multi-center, prospective EU observational study called STRAIT, to evaluate the Safety and Performance of the BOBBY Balloon Guide Catheter for Endovascular Treatment of Acute Ischemic Stroke.

Feb 22, 2022

MicroVention Announces First U.S. Patient Treated with FRED™ X™ Flow Diverter Featuring X Technology

MicroVention, Inc., a subsidiary of Terumo and a global neurovascular company, announced the first U.S. clinical case of its next generation Flow Diverter, the FRED X device, at Thomas Jefferson University Hospital located in Philadelphia.

Jan 12, 2021

Lower-Profile WEB Intrasaccular Aneurysm Treatment Device Receives FDA Approval

The WEB™ Aneurysm Embolization System expands with a lower profile delivery system and new size configurations.

Dec 23, 2020

MicroVention, Inc. Files Trade Secret Lawsuit Against Balt USA, LLC

MicroVention, Inc., a U.S. based subsidiary of Terumo and leading global neurovascular company, announced today the filing of a second lawsuit against Balt USA, LLC and four former employees for trade secret misappropriation.

Sep 22, 2020

MicroVention-Terumo Announces New Leadership

The Company Appoints New President and CEO

Apr 22, 2020

Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide

Contributions include USD 1 million to the COVID-19 Solidarity Response Fund for WHO

Mar 27, 2020

MicroVention's Response to COVID-19

MicroVention has been closely following the daily developments and guidelines surrounding COVID-19, and our commitment remains true as we adjust to the current circumstances that all of us are facing during this challenging time.

Mar 13, 2020

MicroVention Expands Worldwide Innovation Center

Two years after MicroVention, Inc. relocated their Worldwide Innovation Center to 35 Enterprise, the neurovascular company is expanding within the Summit Office Campus to accommodate for their rapid growth.

Jan 8, 2020

MicroVention Announces FDA Premarket Approval of a New Flow Diverter for the Treatment of Brain Aneurysms

MicroVention, Inc., a U.S. based subsidiary of Terumo and a global neurovascular company announced the FDA Premarket Approval (PMA) for the FRED® (Flow Re-Direction Endoluminal Device) device for the treatment of brain aneurysms.

Oct 18, 2019

Treating brain aneurysms before they rupture: How Indiana doctors are using a new aneurysm treatment

The Woven EndoBridge (WEB) Aneurysm Embolization System, approved for use in January, has made its way to Indiana.

Apr 24, 2019

MicroVention Announces Positive Safety and Effectiveness Results in WEB-IT Pivotal Trial Published in Journal of Neurointerventional Surgery

The WEB-IT pivotal trial highlights positive clinical outcomes with the WEB® Aneurysm Embolization System, the only intrasaccular flow disruptor approved in the United States.

Jan 7, 2019

Novel Intrasaccular Aneurysm Treatment Device Receives FDA PMA Approval

The WEB® Aneurysm Embolization System is the first intrasaccular flow disruptor PMA approved for the embolization of wide neck bifurcation aneurysms

Jun 12, 2018

MicroVention Announces FDA Clearance for Thrombectomy Device

Microvention Announces FDA Clearance for Thrombectomy Device. SOFIA® Catheter; A New Device for the Revascularization of Patients with Acute Ischemic Stroke

May 31, 2018

MicroVention® Announces FDA Approval For Neuro Stent Device

The LVIS® and LVIS® Jr. stents are the first stents PMA approved for stent-assisted coil embolization

Sep 26, 2017

MicroVention Celebrates Grand Opening of New Worldwide Innovation Center in Aliso Viejo, California

Microvention Celebrates Grand Opening of New Worldwide Innovation Center in Aliso Viejo, California and also Celebrates 20th Anniversary in New 205,000 Square-Foot Facility

Jun 20, 2017

Orange Country Business Journal Article On MicroVention

Maker of Tiny Devices Goes Big With New Base

Mar 7, 2017

MicroVention and Terumo Corporation Announce Data from Multicenter GREAT Study

Randomized, Controlled, 500-Patient Trial Showed Patients Treated by Hydrogel Coils Less Likely to Have Adverse Outcomes than those Treated by Standard Bare Platinum Coils; Data Presented at International Stroke Conference 2017

Jul 14, 2016

Terumo Corporation Completes Acquisition of Sequent Medical

Unique Aneurysm Embolization Device Complements MicroVention’s Neurovascular Product Portfolio

Jun 15, 2016

Terumo Corporation Acquires Sequent Medical

MicroVention Gains Developer of New Aneurysm Embolization Device

Jun 14, 2016

Terumo Acquires Sequent Medical, U.S.-based Developer of New Aneurysm Embolization Device

Terumo Acquires Sequent Medical, U.S.-based Developer of New Aneurysm Embolization Device

Sep 20, 2015

MicroVention Goes Back to Its Roots

Back to Its Roots: Neurovascular company to come home to much bigger house

Jun 1, 2015

MicroVention to Locate Its New 205,000 Square-Foot Worldwide Headquarters At Summit Office Campus in Aliso Viejo

Groundbreaking Ceremony to be Held June 4, 2015; Occupancy Expected First Half of 2017

Jul 22, 2013

FRED First U.S. Case

MicroVention Announces First Trial Enrollment In Their U.S. Clinical Trial of Its New Dual-Layer Stent For Cerebral Aneurysm Flow Diversion

Mar 6, 2013

MicroVention Costa Rica Plant Opening

MicroVention’s New Manufacturing Plant Facility In Costa Rica Celebrates Grand Opening With Inaugural Plant Ceremony

Jul 2, 2012

HEAT Trial

MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms

Aug 3, 2010

Final Data In International Trial Supports Safety and Effectiveness of MicroVention-Terumo’s HydroCoil® Embolic System for Treatment of Cerebral Aneurysms

Statistically Significant Angiographic Results Show the HydroCoil Embolization System Reduces Major Recurrence Rates in 500-Patient, International Clinical Trial